Senior Technical Team
Dominique Bridon, PhD
Chief Technology Officer
Dr. Dominique Bridon brings 30 years of executive and scientific leadership experience to the Epivax Oncology team. Most recently, he was Chief Executive officer at Biodesy, a company specialized in the detection of conformational changes. He holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistry from the University of Paris XI, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R. Barton as Research Advisor.
Marc Rudoltz, MD
Chief Medical Officer
Marc Rudoltz brings more than two decades of oncology clinical development to EpiVax Oncology's management team. He most recently served as Chief Medical Officer (CMO) for WindMIL Therapeutics (2018), playing a key role in the company’s development strategy for its novel bone marrow derived T‐cell cancer therapy. Marc received a B.S. in Applied Biology from the Massachusetts Institute of Technology (1985), an M.D. from SUNY‐ Upstate Medical University (1989) and completed residency and fellowship training at Thomas Jefferson University (1994) and the University of Pennsylvania (1996), respectively.
Michael Princiotta, PhD
Michael Princiotta brings over 20 years experience in T cell immunology and antigen processing and presentation to Epivax Oncology. Most recently, he was Vice President of Research at Advaxis Immunotherapies where, as head of research, he oversaw the development of a personalized cancer vaccine from conception to Phase I clinical trial. Michael holds a Master of Science in Microbiology and Molecular Biology from the University of Central Florida and a PhD in Microbiology and Immunology from the University of Colorado Health Science Center in Denver Colorado.
Guilhem Richard, PhD
Lead Computational Immunologist
Guilhem Richard brings immunoinformatics expertise to the EpiVax Oncology team. He has been a Computational Immunologist for over 4 years at EpiVax, focusing on refining its immuno-oncology platform. He holds a Master of Engineering in Bioinformatics and Modeling from the National Institute of Applied Science (INSA) of Lyon, France, and a Ph.D. in Bioinformatics from Boston University.
Board of Directors
Daniel Adams, JD
Daniel Adams is the Executive Chairman and Co‐Founder of NextWaveBio, a next‐generation biotechnology enterprise developing safer, more affordable pharmaceuticals. Mr. Adams served as CEO then as the Executive Chairman of Protein Sciences Corporation, a leader in developing and manufacturing vaccines, therapeutics and diagnostics, including Flublok®, a patented, first in class recombinant influenza vaccine, that received licensure from FDA in 2013. The Company was acquired by Sanofi for approximately $750 million. Previously Dan founded and managed several biotechnology companies including Biogen that achieved a combined value of well in excess of $60 billion.